GlaxoSmithKline (LON:GSK) issued its quarterly earnings results on Wednesday. The company reported GBX 111.80 ($1.57) earnings per share for the quarter, beating the Zacks’ consensus estimate of GBX 110.90 ($1.55) by GBX 0.90 ($0.01), Digital Look Earnings reports. GlaxoSmithKline had a net margin of 17.79% and a return on equity of 461.88%. The company had revenue of £76,390 billion during the quarter.
Shares of GlaxoSmithKline (GSK) traded down GBX 12.80 ($0.18) during mid-day trading on Friday, reaching GBX 1,291 ($18.10). The company had a trading volume of 11,683,099 shares, compared to its average volume of 9,220,000. The firm has a market capitalization of $64,010.00 and a price-to-earnings ratio of 4,164.52. GlaxoSmithKline has a 1 year low of GBX 1,235.20 ($17.32) and a 1 year high of GBX 1,724.50 ($24.18).
A number of research firms recently commented on GSK. Goldman Sachs Group restated a “buy” rating and issued a GBX 1,900 ($26.64) price objective on shares of GlaxoSmithKline in a report on Tuesday, October 17th. S&P Global set a GBX 1,500 ($21.03) price target on GlaxoSmithKline and gave the company a “neutral” rating in a report on Thursday, October 26th. HSBC reiterated a “buy” rating and set a GBX 1,925 ($26.99) price target on shares of GlaxoSmithKline in a report on Wednesday, November 22nd. Morgan Stanley set a GBX 1,450 ($20.33) price target on GlaxoSmithKline and gave the company a “sell” rating in a report on Monday, November 6th. Finally, Kepler Capital Markets lowered their price target on GlaxoSmithKline from GBX 1,520 ($21.31) to GBX 1,340 ($18.79) and set a “reduce” rating on the stock in a report on Wednesday, November 1st. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of GBX 1,541.36 ($21.61).
GlaxoSmithKline Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.